Article Sidebar
Main Article Content
Regulatory Role of Long Noncoding RNAs LINC00449 in Hepatocellular Carcinoma Mechanism and Prognosis Via Sponge miR-329-3p/KIF5A Axis
Main Article Content
Abstract
Background/Aims: Hepatocellular carcinoma (HCC) is a globally prevalent malignant tumor with high recurrence and mortality rates. Long noncoding RNAs (lncRNAs) have been utilized to investigate the progression of various cancers, including HCC. The objective of this research is to explore the mechanism and prognostic impact of lncRNA LINC00449 on HCC.
Materials and Methods: LINC00449 and miR-329-3p levels in HCC were measured using RT-qPCR. The impact of high- or lowLINC00449 expression on survival was tested. CCK-8, plate cloning, flow cytometry, and Transwell assays were selected to assess the biological functions of HCC cells. Kaplan–Meier and multivariate Cox analyses were conducted to evaluate the potential of LINC00449 as a prognostic marker for HCC. The interaction between LINC00449, miR-329-3p, and KIF5A was investigated through luciferase activity assays.
Results: LINC00449 expression in HCC tissues was increased. Silencing of LINC00449 improved the survival prospects of patients with HCC. Moreover, LINC00449 targeting the miR-329-3p/KIF5A axis influences the progression of HCC.
Conclusion: LINC00449 may become a biomarker for the prognosis of HCC, and the LINC00449/miR-329-3p/KIF5A regulatory network mediates the deterioration of HCC.
Cite this article as: Tang Y, Lin J, Chi X, Zhang Y, Xing T. Regulatory role of lncRNA LINC00449 in hepatocellular carcinoma mechanism and prognosis via sponge miR-329-3p/KIF5A axis. Turk J Gastroenterol. Published online November 4, 2024. doi 10.5152/tjg.2024.24297
Article Details
References
1. Zou RC, Xiao SF, Shi ZT, et al. Identification of metabolism-associated pathways and genes involved in male and female liver cancer patients. J Theor Biol. 2019;480:218-228. [CrossRef]
2. Galicia-Moreno M, Silva-Gomez JA, Lucano-Landeros S, Santos A, Monroy-Ramirez HC, Armendariz-Borunda J. Liver cancer: therapeutic challenges and the importance of experimental models. Can J Gastroenterol Hepatol. 2021;2021:8837811. [CrossRef]
3. Xie J, Chen L, Sun Q, et al. An immune subtype-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing analysis. Aging. 2022;14(7):3276-3292. [CrossRef]
4. Lim LJ, Ling LH, Neo YP, et al. Highly deregulated lncRNA LOC is associated with overall worse prognosis in Hepatocellular Carcinoma patients. J Cancer. 2021;12(11):3098-3113. [CrossRef]
5. Qiu J, Zhang S, Wang P, et al. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway. Cancer Med. 2020;9(21):8159-8172. [CrossRef]
6. Wang H, Feng Q, Wu Y, et al. Association of circulating long noncoding RNA HULC expression with disease risk, inflammatory cytokines, biochemical index levels, severity-assessed scores, and mortality of sepsis. J Clin Lab Anal. 2021;35(3):e23656. [CrossRef]
7. Zhao Y, Teng H, Yao F, Yap S, Sun Y, Ma L. Challenges and strategies in ascribing functions to long noncoding RNAs. Cancers. 2020;12(6):1458. [CrossRef]
8. Zhao S, Li P, Zhou G. Long noncoding RNAs in the prediction of survival of patients with digestive cancers. Turk J Gastroenterol. 2023;34(1):19-25. [CrossRef]
9. Wang X, Zhang J, Liu X, Wei B, Zhan L. Long noncoding RNAs in endometriosis: biological functions, expressions, and mechanisms. J Cell Physiol. 2021;236(1):6-14. [CrossRef]
10. Yang Z, Tang N, Zheng M, Chang Y. Exosomal long noncoding RNAs serve as biomarkers for liver disease. Turk J Gastroenterol. 2023;34(7):674-680. [CrossRef]
11. Wu H, Liu T, Qi J, Qin C, Zhu Q. Four autophagy-related lncRNAs predict the prognosis of HCC through coexpression and ceRNA mechanism. BioMed Res Int. 2020;2020:3801748. [CrossRef]
12. Wang Y, Yang L, Chen T, et al. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Mol Cancer. 2019;18(1):28. [CrossRef]
13. Wang G, Sun L, Wang S, et al. Ferroptosis-related long noncoding RNAs and the roles of LASTR in stomach adenocarcinoma. Mol Med Rep. 2022;25(4):118. [CrossRef]
14. Ping J, Huang S, Wu J, et al. Association between lincRNA expression and overall survival for patients with triple-negative breast cancer. Breast Cancer Res Treat. 2021;186(3):769-777. [CrossRef]
15. Zhang S, Li X, Tang C, Kuang W. Inflammation-related long noncoding RNA signature predicts the prognosis of gastric carcinoma. Front Genet. 2021;12:736766. [CrossRef]
16. Dong C, Huang S, Sun L, Yao J, Yan J, Yin X. DLGAP4 acts as an effective prognostic predictor for hepatocellular carcinoma and is closely related to tumour progression. Sci Rep. 2022;12(1):19775. [CrossRef]
17. Zhao WT, Han LX, Liu L, et al. The Yunnan national medicine Maytenus compound inhibits the proliferation of hepatocellular carcinoma (HCC) by suppressing the activation of the EGFR-PI3K-AKT signaling pathway. J Cancer. 2021;12(11):3325-3334. [CrossRef]
18. Zhou T, Zhang W, Cheng D, Tang X, Feng J, Wu W. Preparation, characterization, and in vivo evaluation of NK4-conjugated hydroxycamptothecin-loaded liposomes. Int J Nanomedicine. 2020;15:2277-2286. [CrossRef]
19. Leone P, Solimando AG, Fasano R, et al. The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment. Vaccines. 2021;9(5):532. [CrossRef]
20. Liu J, Zhang H, Xia P, et al. Genome stability-related lncRNA ZFPM2-AS1 promotes tumor progression via miR-3065-5p/XRCC4 in hepatocellular carcinoma. Int J Oncol. 2023;62(2):19. [CrossRef]
21. Xu B, Li C, Yang B, et al. LncRNA SNHG20 silencing inhibits hepatocellular carcinoma progression by sponging miR-5095 from MBD1. Am J Transl Res. 2023;15(6):4314-4331.
22. Wang F, Hu Y, Wang H, et al. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2. J Exp Clin Cancer Res. 2023;42(1):267. [CrossRef]
23. Liu R, Yin G, Tuo H, et al. METTL3-induced lncRNA GBAP1 promotes hepatocellular carcinoma progression by activating BMP/SMAD pathway. Biol Direct. 2023;18(1):53. [CrossRef]
24. Sun J, Li Y, Shi M, et al. A positive feedback loop of lncRNA HOXD-AS2 and SMYD3 facilitates hepatocellular carcinoma progression via the MEK/ERK pathway. J Hepatocellular Carcinoma. 2023;10:1237-1256. [CrossRef]
25. Wang Y, Cao K. KDM1A promotes immunosuppression in hepatocellular carcinoma by regulating PD-L1 through demethylating MEF2D. J Immunol Res. 2021;2021:9965099. [CrossRef]
26. Xin RQ, Li WB, Hu ZW, Wu ZX, Sun W. MiR-329-3p inhibits hepatocellular carcinoma cell proliferation and migration through USP22-Wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci. 2020;24(19):9932-9939. [CrossRef]
27. Nakano J, Chiba K, Niwa S. An ALS-associated KIF5A mutant forms oligomers and aggregates and induces neuronal toxicity. Genes Cells. 2022;27(6):421-435. [CrossRef]
28. Guo X, Wang Y. LncRNA TMPO-AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR-329-3p to stimulate FOXK1-mediated AKT/mTOR signaling pathway. Cancer Med. 2020;9(14):5235-5246. [CrossRef]